XXII catalysts and trendline, YTD.

With FDA planning to regulate nicotine levels, XXII (holding 200 patents protecting their production/manufaturing methods for making VLN, very low nicotine, tobacco) is well positioned to capitalize on the ~$20b of Big Tobacco market cap lost since July. In July, the FDA publicly announced their ambitions to change tobacco regulation. In addition, the FDA has invested $100m of capital to fund studies which involved XXII cigarettes. Recently, XXII had completed their Phase 3 Study, which provided data that an immediate reduction in nicotine levels produces the least amount of harm to smokers. This data may prove a talking point at the 10/26 and 10/27 conference where tobacco industry and legislative leaders will meet to discuss the future of tobacco regulation. On top of this, on the 11th of October, XXII closed an RDO that raised $54m in capital (enough runway for 5 years of operating expenses) to an undisclosed institution(s). This entity has 10 days to disclose their stake which means by the 20th, because the 21st is on a weekend. This represents a 16% ownership of the company, and given the current climate I think it is foreshadowing a partnership deal. The timing couldn't be better, with just two weeks until the start of the upcoming conference, I think 22nd Century Group is in store for a very rewarding month.
Hope u are right. In since 1.81
ZH 简体中文
EN English
EN English (UK)
EN English (IN)
DE Deutsch
FR Français
ES Español
IT Italiano
PL Polski
SV Svenska
TR Türkçe
RU Русский
PT Português
ID Bahasa Indonesia
MS Bahasa Melayu
TH ภาษาไทย
VI Tiếng Việt
JA 日本語
KO 한국어
ZH 繁體中文
AR العربية
HE עברית
首页 股票筛选器 外汇筛选器 加密货币筛选器 财经日历 如何运作 图表功能 网站规则 版主 网站 & 经纪商解决方案 插件 图表库 功能请求 博客 & 新闻 常见问题 帮助 & 维基 Twitter
概述 个人资料设置 账号和账单 我的客服工单 联系支持 已发表观点 粉丝 正在关注 私人消息 聊天 退出